Abnormal Temporal Slowing on EEG Findings in Preclinical Alzheimer's Disease Patients With the ApoE4 Allele: A Pilot Study

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Nov 29

PMID 38021568

Authors

Nathan N Kim

Charissa Tan

Enze Ma

Selin Kutlu

Enrique Carrazana

Vajjhala Vimala

Jason Viereck

Kore Liow

Affiliations

Soon will be listed here.

Abstract

Introduction: Currently, there are limited accessible and cost-effective biomarkers for preclinical Alzheimer's disease (AD) patients. However, the apolipoprotein E (ApoE) polymorphic alleles can predict if someone is at high (e4), neutral (e3), or low (e2) genetic risk for developing AD. This study analyzed electroencephalogram (EEG) reports from individuals with various ApoE genotypes, aiming to identify EEG changes and patterns that could potentially serve as predictive markers for preclinical AD progression.

Methods: Participants aged 64-78 were selected from the patient database at an outpatient neurology clinic. Genotype studies were performed to determine ApoE status, followed by EEG analysis to identify any apparent trends. A case-control design was used, categorizing participants into cases (e2e3, e2e4, e3e4, e4e4) and controls (e3e3). EEG recordings were compared between the groups to identify potential differences in EEG characteristics, including abnormal temporal slowing, frequency, and ApoE genotype association.

Results: Among 43 participants, 49% demonstrated evidence of abnormal temporal slowing on EEG. Of these, 48% displayed focal left temporal slowing, and 52% displayed bilateral temporal slowing. The right-sided temporal slowing was not observed. Among participants with abnormal slowing, 95% exhibited theta frequency (4-8 Hz) slowing, while only 4.8% displayed delta frequency (0-4 Hz) slowing. Among participants with the ApoE4 allele, 61.5% demonstrated evidence of abnormal slowing, compared to 43.3% without it. Furthermore, the presence of an ApoE4 allele was associated with a significantly higher proportion of males (54%) compared to those without it (13%) (p=0.009).

Conclusions: Although we did not find a statistically significant difference in temporal EEG slowing among different ApoE genotypes, our findings suggest a potential association between temporal slowing on EEG and the presence of an ApoE4 allele in individuals with preclinical AD. These observations highlight the need for further exploration into the potential influence of the ApoE4 allele on EEG findings and the utility of EEG as a complementary diagnostic tool for AD. Longitudinal studies with large sample sizes are needed to establish the precise relationship between EEG patterns, ApoE genotypes, and AD progression.

References

Tsolaki A, Kazis D, Kompatsiaris I, Kosmidou V, Tsolaki M . Electroencephalogram and Alzheimer's disease: clinical and research approaches. Int J Alzheimers Dis. 2014; 2014:349249. PMC: 4020452. DOI: 10.1155/2014/349249. View

Smailovic U, Johansson C, Koenig T, Kareholt I, Graff C, Jelic V . Decreased Global EEG Synchronization in Amyloid Positive Mild Cognitive Impairment and Alzheimer's Disease Patients-Relationship to . Brain Sci. 2021; 11(10). PMC: 8533770. DOI: 10.3390/brainsci11101359. View

Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261(5123):921-3. DOI: 10.1126/science.8346443. View

Ponomareva N, Andreeva T, Protasova M, Konovalov R, Krotenkova M, Kolesnikova E . Genetic association of apolipoprotein E genotype with EEG alpha rhythm slowing and functional brain network alterations during normal aging. Front Neurosci. 2022; 16:931173. PMC: 9376365. DOI: 10.3389/fnins.2022.931173. View

Gaubert S, Raimondo F, Houot M, Corsi M, Naccache L, Sitt J . EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. Brain. 2019; 142(7):2096-2112. DOI: 10.1093/brain/awz150. View

Belloy M, Napolioni V, Greicius M . A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. Neuron. 2019; 101(5):820-838. PMC: 6407643. DOI: 10.1016/j.neuron.2019.01.056. View

Gamache J, Yun Y, Chiba-Falek O . Sex-dependent effect of on Alzheimer's disease and other age-related neurodegenerative disorders. Dis Model Mech. 2020; 13(8). PMC: 7473656. DOI: 10.1242/dmm.045211. View

Jeong J . EEG dynamics in patients with Alzheimer's disease. Clin Neurophysiol. 2004; 115(7):1490-505. DOI: 10.1016/j.clinph.2004.01.001. View

Atri A . The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. Med Clin North Am. 2019; 103(2):263-293. DOI: 10.1016/j.mcna.2018.10.009. View

10.

Payami H, Montee K, Kaye J, Bird T, Yu C, Wijsman E . Alzheimer's disease, apolipoprotein E4, and gender. JAMA. 1994; 271(17):1316-7. View

11.

Fan J, Tao W, Li X, Li H, Zhang J, Wei D . The Contribution of Genetic Factors to Cognitive Impairment and Dementia: Apolipoprotein E Gene, Gene Interactions, and Polygenic Risk. Int J Mol Sci. 2019; 20(5). PMC: 6429136. DOI: 10.3390/ijms20051177. View

12.

Jelic V, Julin P, Shigeta M, Nordberg A, Lannfelt L, Winblad B . Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. J Neurol Neurosurg Psychiatry. 1997; 63(1):59-65. PMC: 2169641. DOI: 10.1136/jnnp.63.1.59. View

13.

Pedroso R, Jose Fraga F, Nascimento C, Pott-Junior H, Cominetti M . Apolipoprotein E ε4 allele impairs cortical activity in healthy aging and Alzheimer's disease. Behav Brain Res. 2021; 420:113700. DOI: 10.1016/j.bbr.2021.113700. View

14.

Smailovic U, Jelic V . Neurophysiological Markers of Alzheimer's Disease: Quantitative EEG Approach. Neurol Ther. 2019; 8(Suppl 2):37-55. PMC: 6908537. DOI: 10.1007/s40120-019-00169-0. View

15.

Babiloni C, Blinowska K, Bonanni L, Cichocki A, de Haan W, Percio C . What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiol Aging. 2019; 85:58-73. DOI: 10.1016/j.neurobiolaging.2019.09.008. View

16.

Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

17.

Percio C, Lopez S, Noce G, Lizio R, Tucci F, Soricelli A . What a Single Electroencephalographic (EEG) Channel Can Tell us About Alzheimer's Disease Patients With Mild Cognitive Impairment. Clin EEG Neurosci. 2022; 54(1):21-35. DOI: 10.1177/15500594221125033. View

18.

Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E . Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol. 2010; 67(2):217-23. DOI: 10.1001/archneurol.2009.316. View

19.

Hatz F, Benz N, Hardmeier M, Zimmermann R, Rueegg S, Schindler C . Quantitative EEG and apolipoprotein E-genotype improve classification of patients with suspected Alzheimer's disease. Clin Neurophysiol. 2013; 124(11):2146-52. DOI: 10.1016/j.clinph.2013.04.339. View

20.

Wolf A, Caselli R, Reiman E, Valla J . APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease. Neurobiol Aging. 2012; 34(4):1007-17. PMC: 3545040. DOI: 10.1016/j.neurobiolaging.2012.10.011. View